| abstract |
The disclosure provides fusion proteins that contain two TGF-β binding domains of TGF-β type Il receptor joined to each other by a linker. For example, the C terminus of the first TGF-β binding domain is joined by a short peptide linker (e.g., a 9-glycine linker) to the N terminus of the second TGF-β binding domain. Despite the proximity of the C terminus of the first domain to N terminus of the second domain, such a fusion protein effectively neutralizes TGF-β, in some cases, similarly to anti-TGF-β antibodies. |